ProSense™ – Liquid Nitrogen-Based Cryoablation System
Minimally Invasive Tumor Ablation – Precision Freezing for Optimal Outcomes
ProSense™ – Liquid Nitrogen-Based Cryoablation System
Minimally Invasive Tumor Ablation – Precision Freezing for Optimal Outcomes
The ProSense™ Cryoablation System by IceCure Medical offers a cutting-edge, minimally invasive solution for the treatment of benign and malignant tumors. Utilizing ultra-low temperatures achieved through liquid nitrogen, ProSense™ effectively destroys targeted tissue by freezing, providing an alternative to traditional surgical procedures.
Designed for versatility, ProSense™ is suitable for use in various clinical settings, including office-based environments and radiology departments. The system’s compact design, coupled with its user-friendly interface, allows for seamless integration into existing medical workflows.
ProSense™ has demonstrated efficacy in treating a range of tumors across multiple specialties, including:
- Breast Tumors: Effective in treating fibroadenomas and early-stage breast cancers, offering a less invasive option with favorable cosmetic outcomes.
- Lung, Liver, and Kidney Tumors: Provides a non-surgical approach to ablate tumors in vital organs, minimizing patient recovery time.
- Musculoskeletal Tumors: Applicable in orthopedic oncology for the treatment of bone tumors.
The system’s cryoprobes come in various sizes, allowing for tailored treatment plans based on tumor size and location. Real-time imaging guidance ensures precise probe placement and monitoring of the ablation process.
Clinical studies have highlighted ProSense™’s safety and effectiveness, with patients experiencing minimal discomfort and rapid return to daily activities. The procedure’s minimally invasive nature reduces the risk of complications commonly associated with open surgeries.
ProSense™ has received regulatory approvals in multiple countries, reflecting its global acceptance as a reliable cryoablation solution.
The ProSense™ Cryoablation System by IceCure Medical offers a cutting-edge, minimally invasive solution for the treatment of benign and malignant tumors. Utilizing ultra-low temperatures achieved through liquid nitrogen, ProSense™ effectively destroys targeted tissue by freezing, providing an alternative to traditional surgical procedures.
Designed for versatility, ProSense™ is suitable for use in various clinical settings, including office-based environments and radiology departments. The system’s compact design, coupled with its user-friendly interface, allows for seamless integration into existing medical workflows.
ProSense™ has demonstrated efficacy in treating a range of tumors across multiple specialties, including:
- Breast Tumors: Effective in treating fibroadenomas and early-stage breast cancers, offering a less invasive option with favorable cosmetic outcomes.
- Lung, Liver, and Kidney Tumors: Provides a non-surgical approach to ablate tumors in vital organs, minimizing patient recovery time.
- Musculoskeletal Tumors: Applicable in orthopedic oncology for the treatment of bone tumors.
The system’s cryoprobes come in various sizes, allowing for tailored treatment plans based on tumor size and location. Real-time imaging guidance ensures precise probe placement and monitoring of the ablation process.
Clinical studies have highlighted ProSense™’s safety and effectiveness, with patients experiencing minimal discomfort and rapid return to daily activities. The procedure’s minimally invasive nature reduces the risk of complications commonly associated with open surgeries.
ProSense™ has received regulatory approvals in multiple countries, reflecting its global acceptance as a reliable cryoablation solution.
- High reproducibility with programmable user profiles
- Modular configuration across monopolar, bipolar, APC, and waterjet
- Custom energy delivery profiles for each specialty
- Compact footprint and plug-and-play adaptability
- Integrated safety monitoring for patients and instruments
- Multi-language touchscreen interface for intuitive control
Trusted Partners
